Today, we celebrate National Intern Day and recognize our amazing #Dynamo interns who share our commitment to bring transformative therapies to people living with serious muscle diseases. Thank you for all your hard work and dedication!
Dyne Therapeutics
Biotechnology Research
Waltham, Massachusetts 12,462 followers
Advancing life-transforming therapies for serious muscle diseases
About us
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com. To view our community guidelines, click here: https://bit.ly/3BYPnpK
- Website
-
http://www.dyne-tx.com
External link for Dyne Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
1560 Trapelo Rd
Waltham, Massachusetts 02451, US
Employees at Dyne Therapeutics
-
Marcel Meth
SharePoint Consultant/Developer/Analyst (Intranets, Document Management, Collaboration & AIs)
-
Jason Rhodes
-
Michael Tobin
VP, Head of Technology at Dyne Therapeutics, improving patients' lives by straddling high tech and biotech in truly innovative life science…
-
Clarence J. Wang
VP, Head of Data Sciences
Updates
-
We’re pleased to sponsor Team Joseph's first ever “What Now?” virtual conference. Learn more and register for this community event that focuses on older adolescents and adults with #Duchenne: https://bit.ly/3y5svX1
-
-
Our #Dynamos gathered for our third annual FORCE for Good Service Day, dedicating the day to supporting local nonprofits in the #Boston area. Thank you to our wonderful partners at Life Science Cares Boston for the opportunity to make a positive impact and give back to our community! The Food Project Cradles to Crayons Massachusetts Community Servings STEAM Ahead MSPCA-Angell Mystic River Watershed Association
-
On July 12, we’re joining the Myotonic Dystrophy Foundation for a “Meet the DM Drug Developers” webinar. We will discuss the recent ACHIEVE clinical trial data for our investigational medicine, DYNE-101. Following the presentation, our Chief Medical Affairs Officer, Ash Dugar, will participate in a live Q&A. Don’t forget to register in advance to submit your questions! https://bit.ly/3WcJGPR #MyotonicDystrophy
-
-
Join us at the 4th Annual Oligonucleotides for CNS Summit. Catch our presentation about our proprietary FORCE™ Platform and hear about data demonstrating its ability to achieve delivery to muscle & the central nervous system (CNS): See the agenda: https://bit.ly/4cynFAF
-
-
We’re excited to join the DMD community for a webinar with Defeat Duchenne Canada on July 8. Register to learn about the clinical data from our DELIVER trial of DYNE-251, a potential therapeutic for people living with #DMD who are amenable to exon 51 skipping: https://bit.ly/3VEuR8i #Duchenne #patientadvocacy #clinicaltrial
-
-
On July 3rd, we’ll join CureDuchenne for a webinar about the efficacy and safety data from the DELIVER trial of DYNE-251, an investigational therapeutic for people with #DMD amenable to exon 51 skipping: https://bit.ly/3zvfpTf #clinicaltrial #drugdevelopment
-
We’re excited to join the #Duchenne community for the Parent Project Muscular Dystrophy's 2024 Annual Conference! Catch the presentation on clinical data from the DELIVER study on Friday, June 28th, during the “Research Row: Strategies to Restore Dystrophin Session.” Register here: https://bit.ly/3VZr3yE
-
-
Bright, motivated, driven, and energetic are just a few of the characteristics of a #Dynamo. Listen to our team describe the unique attributes of employees and visit our website to learn more about working at Dyne: https://bit.ly/3VSQPod #STEMcareers #biotechnology #innovation
-
Today we announced new preclinical data demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to muscle and CNS in Pompe disease. Read more: https://bit.ly/4bhbZkc
-